CD163 and cancer: To investigate the role of immune cells in patients with R/M EC undergoing treatment with Pembrolizumab plus Lenvatinib, we examined the infiltration of CD8+ T lymphocytes, CD20+ B lymphocytes, FoxP3+ T lymphocytes, and CD163+ macrophages within the tumor tissue of 28 cancer patients before immunotargeted therapy.